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Abortifacient Vaccine Technology: 
Overview, Hazards, and Christian Response 
by 
Lawrence F. Roberge, M.S. 
The author is a biotechnology consultant and information broker. He worked for 
four years (at NERAC, Inc., a former NASA-affiliated technology transfer 
facility) advising companies across the United States, Canada, and Europe. He 
advises on business, regulatory, patent, and technical issues for the biotechnology, 
aerospace, chemica£ pharmaceutica£ medical diagnostic, agro-biotechnology, 
cosmetic, and medical device industries. 
Recent developments in vaccine technology and biotechnology in general 
have advanced a new version of abortion under the semblance of birth control. 
Funded by various international agencies (particularly the World Health 
Organization), research over the past 20 years is coming close to the development 
and marketing of several types of vaccine technology whose sole purpose is to 
terminate a pregnancy (i.e. induce an abortion). Abortifacient vaccines (also 
termed antifertility vaccines, or contragestational vaccine) are defined as vaccines 
that act to sensitize the maternal immune system to terminate a pregnancy either 
by blocking a mechanism of pregnancy (i.e. human chorionic gonadotropin) or 
by the immune system attacking and killing the embryo (usually prior to 
nidation). The end result is a very early stage first trimester abortion. 
This paper explores abortifacient vaccine technology and the repercussions on 
abortion, the vaccine recipient, and the pro-life movement. This paper strongly 
urgeS that the pro-life movement prepare clear teachings on the evils of this 
technology, the resultant abortion effects, and the health hazards involved with 
this technology. 
Types of Abortifacient Vaccine 
A. Human Chorionic Gonadotropin (beG) Vaccine 
Several variations of the abortifacient vaccine are under development: the 
hCG vaccine and the TBA vaccine. 
The first generation vaccine research led by Dr. Vernon C. Stevens l at Ohio 
State University and by Dr. G.P. Talwar2 at the National Institute of 
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Immunology, New Delhi, India, have brought closer the dawn of a new form of 
abortion. 
Since the 1970's, under support from the World Health Organization (WHO), 
research has been directed at immunologically blocking conception or the 
immunological termination of a pregnancy. One key target has been the 
hormone, human Chorionic Gonadotropin (hCG). This hormone created by the 
developing embryo signals the maintenance of the corpus lutem which provides 
progesterone and estrogen to maintain the vascularization of the uterine 
endometrium during the first few months of pregnancy. Should hCG levels drop 
in the first critical 6 to 10 weeks, the uterine vascularization would break down, 
resulting in the death of the developing embryo while the uterine endometrium 
sloughs off the uterine wall. HCG is similar in structure and chemistry to other 
glycosylated peptide hormones (e.g. Thyroid Stimulating Hormone (TSH), 
Luteinizing Hormone (LH), and Follicle Stimulating Hormone (FSH); being 
composed of two glycosylated peptide chains (alpha and beta). While the hCG 
alpha chain is nearly identical to other glycosylated peptide hormones, the hCG 
beta chain is more distinct biochemically. 
Early studies to develop a vaccine against hCG were hampered by 
immunogenic cross reactivity with FSH, TSH, or LH, due to nearly identical 
alpha peptide chain sequences. Research focused on the hCG beta chain, but it 
shares 85 per cent sequence commonality for the first 110 amino acids with LH. 
Therefore, the focus shifted to the last 35 amino acid sequence of hCG which is 
sufficiently different from LH. This subunit of the hCG beta chain, now referred 
to as the hCG beta peptide fragment, has served as the focal immunogen in the 
development of a hCG vaccine. Further versions have inculded linking the hCG 
beta peptide fragment to various carrier molecules (e.g. tetanus or diphtheria 
toxoids) to enhance immune responses to the hCG peptide. 
Recent research has begun to bear fruit at various facilities across the globe. 
Phase II studies for the Stevens vaccine are still in progresss, but Talwar's group 
reports2 that early Phase II studies indicate that sexually active women sustained 
high antibody titers to hCG and were prevented from getting pregnant. No major 
side effects were reported in either the Phase P or early Phase II trials2• 
Furthermore, Phase I trials detected no significant changes in the peptide or 
steroid endocrine parameters. 14 Presumably, the high levels of antibodies acted to 
remove hCG molecules from the blood. This would cause any developing 
embryo to fail uterine implantation (AKA nidation) and pass out during 
menstruation. 
As no disruption of the ovulatory cycle or menstrual cycle was reported, it 
could be presumed that the embryo passed from the Fallopian tube into the 
uterus and never achieved complete endometrial implantation. Stevens reports 
that it is possible that the vaccine might not merely encourage humoral 
(antibody-based) immuity, but may cause cellular (lymphocyte-based) 
immunity. Since the trophoblast layer of the embryo produces and secretes hCG. 
Stevens states that it is possible that sensitized lymphocytes may attack and 
destroy the trophoblastic cells of the peri-implantation blastocyst (embryo). 
Talwar and Stevens' work suggests that this vaccine could last beyond the 
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initial six months that Phase I studies describe. Further improvements in the 
vaccine, including those based on monkey trials which used delayed release 
biodegradable microspheres to achieve active immunization lasting 2 years2, 
indicated that a long lasting hCG vaccine is now within reach for human use. 
Talwar4 has stated that he has been contacted by pharmaceutical firms from 
Korea, Indonesia, France, and Holland, but not yet from the United States. 
As recent events have demonstrated, the marketing and distribution of an 
abortifacient medical product (e.g. RU-486) outside ofthe United States can still 
eventually be brought into the United States under the miasma of political 
rhetoric, and with the assistance of non-profit groups like The Population 
Council. With social and political organizations promoting a pro-choice/pro-
abortion agenda, any device that offers simplicity of use, longevity of effect, and 
little evidence of side effects becomes an attractive product to promote in the 
United States. The hCG vaccine is such a device. With rapidly advancing vaccine 
technology, the hCG vaccine could become easily accessible in the next few 
years; and with improvements, could attain a 5 year efficacy life-span between 
booster vaccinations. 
Furthermore, ready acceptance in developing countries, Europe, Japan, and 
the Pacific rim nations, would add further political/social pressure to allow 
acceptance within the United States under the guise of contraceptive choice and 
population control. 
Clearly the hCG vaccine is nearing complete development. With its absence of 
major side effects, convenience of use, and guarantee of zero pregnancies, the 
hCG vaccine appears attractive to a world market desperately searching for more 
effective methods of birth control. Yet the hCG vaccine's method of action is 
clearly abortifacient. As the hCG vaccine enters into the final vaccine testing 
phases and eventual marketing, it must be up to the Church as a whole not be 
lulled into complacency by world market acceptance, but rather to develop an 
appropriate response to this "abortion vaccine". 
B. Trophoblastic Antigen (TBA) Vaccine 
The second generation abortifacient vaccine is called the Trophoblastic 
Antigen (TBA) vaccine. Early research funded by the World Health 
Organization (WHO) special program of research in human reproduction 
continues to develop another type of birth control vaccine which will abort an 
early stage embryo.6,7 
Touted as contragestational vaccines (i.e. vaccines that block the development 
and growth of life during the gestation period which lasts from fertilization of the 
human egg to the delivery of the baby), work has focused on the isolation of a select 
antigen on the trophoblastic layer of the human embryo. The outer layer of the 
trophoblast (the layer of cells which helps the embryo implant into the mother's 
uterine lining and later forms the placenta), called the trophoectoderm, is the target 
from which a vaccine would be devised. Antibodies will select a unique protein on 
the surface of the trophoectoderm. This protein will be the antigen from which a 
vaccine will be developed. The vaccine will in turn "teach" the woman's immune 
system that the early embryo is foreign and must be destroyed. 
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The eventual protocol for the TBA vaccine is similar to the hCG vaccine.9 The 
woman's immune system is trained to consider the antigen (i.e. the trophoectoderm 
surface protein) foreign and will then mount an immune response (cellular or 
antibody-based or both) against the trophoblastic layer of the embryo. This will 
destroy the early embryo prior to implantation within the uterine endometrium. 
The woman has no disruption of her menstrual cycle or menses. It is thought that 
the woman would never know that she was pregnant. It is hoped that this vaccine, 
touted as a form of birth control, will last one or more years in efficacy. 
Although recent research has been focused on tissue culture and animal 
studies6,7, the research will eventually require human studies. These human studies 
will include dissection of early human embryos (referred to as pre-embryos, if they 
are less than 14 days post-fertilization). This research on pre-embryos is deemed 
acceptable under guidelines developed by the Ethics Committee of the American 
Fertility Society. IF such research would provide new information not otherwise 
obtainable.s In the pursuit of trophoectoderm antigen vaccines, such research 
might be deemed acceptable. 
It must be noted that the committee states that the pre-embryo (because of their 
early developmental state and that they have not yet achieved uterine 
implantation) deserves respect beyond human tissue, but NOT the respect of an 
individual person (emphasis this author). Basically, if the pre-embryo is not going 
to be implanted into a uterus (to grow into a human infant) and if basic research 
would gain valuable information, then dissection of human pre-embryos, 
especially to verify early presence of antigens to be used in "birth control" vaccines 
would be permitted. The dissection studies would be used to determine the early 
presence of antigens that the abortifacient vaccine would be targeting. The premise 
is that the earlier the presence of the antigen, the earlier the vaccine primed 
immune system can detect and then destroy the embryo. Finally, human vaccine 
trials (similar to the hCG vaccine trials presently underway 9, 10) would then 
commence. 
This research may now be accelerated due to the recent National Institute of 
Health's (NIH) ad hoc committee report on Human Embryo Research. ls This 
report's conclusions clearly support human embryo research for the development 
of "birth control" vaccines. 
This potential vaccine offers similar promises and hazards (to be discussed later 
in this text) to the hCG vaccine.ll Both would induce an abortion of an early 
embryonic life. Both would be touted as "birth control" that is long lasting, low 
maintenance, and easily available. 
Unfortunately, the WHO continues to fund this research. Dr. C.S. Bambra6 at 
the Institute of Primate Research in Nairobi, Kenya,indicates that animal model 
studies on baboons are the next step in the development of this vaccine. Although 
these studies are less developed than the hCG vaccine 9,10, 11 , the TBA vaccine must 
be viewed by society and the prolife movement for what they really are - an 
abortifacient vaccine. 
Problems and Hazards 
NOTE- that although of much the comments below focus on the hCG vaccine, 
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(due to its more developed status) the problems and hazards could apply equally to 
the TBA vaccine. 
A. Abortion 
Several points must be addressed with regards to abortifacient vaccine use. First, 
clearly this vaccine induces an abortion of a developing embryo each month (when 
such embryo is conceived). Whereas Talwar's studies demonstrate that menstrual 
and ovulatory cycles were maintained and regular2,3, it then becomes easy to 
understand that hCG vaccines cause one abortion per ovulatory cycle (if the 
woman is sexually active); ergo, 12 ovulation cycles per year, 12 abortions per year. 
This clearly conflicts with Biblical and Church teaching on the sanctity of life and 
God's abomination towards abortion. 
Furthermore, as mentioned earlier, research leading to the development of the 
TBA vaccine will require the dissection of human embryos to determine the 
appropriate tropohoblastic surface antigen to focus the immune response against 
This would further degrade human life and if sanctioned, would further degrade 
Christian teaching on the sanctity of life. 
B. Health Hazards to Mother (Vaccine Recipient) 
Secondly, although hCG titer studies have lasted less than one year, no large scale 
and long term (5 or more years) studies have been conducted. No studies have 
addressed the possibility that if the immune system is repeatedly exposed to the 
immunogen (hCG), then could the subject eventually become "immunologically 
sterile". That is, a subject would be fertile for having and regularly producing 
healthy oocytes, capable of having the oocyte fertilized and travel through the 
Fallopian tubes, but because the immune system attacks the hCG blood levels (and 
perhaps the hCG producing trophoblast cells of the embryo), the developing 
embryo/life will never come to termlbirth. 
Also, a recent study by Dirnhofer, et a/l~ suggests that the vaccine may induce an 
autoimmune reaction to the ovaries. If this occurs, premature menopause could occur, 
followed by the risk of osteoporosis and the increased risk of cardiovascular disease. 
Should later hCG vaccine recipients develop this situation, this author wonders if 
WHO funding would be directed to address it (Perhaps by development of an 
anti-idiotype vaccine.). 
In a similar fashion, it is conceivable that TBA vaccines could also render women 
"immunologically sterile". It must be stressed that this vaccine will focus its action 
solely on the developing embryo. 
C. Tool of "Forced" Birth Control 
Thirdly, this vaccine could become an abused tool to "control conception". In 
developing countries, forced sterilization and abortion have been considered or 
actively used as policies to achieve reductions in population growth. Applications of 
hCG vaccines could be applied either by force or coercion (e.g. withholding 
employment, voting rights, or health care, to women that refuses hCG booster 
vaccinations). 
Even within the United States, this vaccine could become abused. Instead of 
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handing sexually active adolescents condoms and other contraceptives, hCG 
vaccines could be a parentall societal response to adolescents who refuse sexual 
abstinence. Furthermore, the application of the hCG vaccine could become the 
answer to deal with other reproductively related societal problems. An hCG 
vaccine could be court-mandated to prevent child abusing women from having 
any more children which they might later abuse. As some individuals, like Dr. 
Joycelyn Elders have suggested, birth control could be the answer to poverty, 
crime, and other social problems; it could be suggested that further welfare 
support would become dependent on young mothers suppressing further births 
by using the hCG vaccine. 
D. Effects on Pro-Life Movement and the Church 
Will abortifacient vaccines affect the man-in-the-street or church pro-life 
teaching at large? Perhaps. Will pro-life and lobbying lose some of their influence 
and political might? Maybe. Will the abortion debate be rendered to an issue 
(which as Supreme Court Judge Ruth Bader Ginsburg has stated) of a private 
decision within a doctor's office? Yes, it could. 
How? 
Consider the following points. One main arena in the marketplace of ideas 
where pro-life protests, sidewalk counselors, and public notice of the pro-life 
message occurs is in front of an abortion clinic or hospital. It is important to note 
that RU-486 market studies predict that the drug will replace 30-60% of clinical 
legal abortions. 13 Abortion vaccines could replace 90% (or more) of the clinical 
legal abortions, while at the same time being touted as a safe, effective, long term 
form of birth control. While such health data sources such as the Centers for 
Disease Control (CDC) and the Alan Guttmacher Institue (AGI) will record a 
drop in legal induced abortions (due to abortifacient vaccine use), the true 
number of abortions will rise exponentially! 
Furthermore, one method that pro-life uses to convey the "humanness" ofthe 
fetus is to display graphic photos offetuses with well formed fingers, eyes, hands, 
toes, a heart beating, etc. Abortifacient vaccines act to destroy the life in the 
embryonic (i.e. trophoblastic stage) stage, well BEFORE toes, eyes, hands, etc. 
are formed. Also, it will be harder to "emotionally associate" with a hollow ball 
of cells (the trophoblastic embryo) than with a human-shaped fetus.In essence, 
the myth that abortion removes just a "blob of cells or tissue" will be reinforced. 
Beyond the reduction in clinical abortions (and perhaps abortion clinics) and 
the problems of defining and developing emotional compassion unto the embryo, 
pro-life forces must deal with vaccine distribution. Whereas pro-life forces have 
had to deal with hundreds of abortion clinics and hospitals across the United 
States, abortion vaccine will be distributed in the oflices of tens of thousands of 
OB/GYN doctors. While some pro-life leaders have admitted that getting 
sufficient numbers of protestors, sidewalk counselors, and other supporters at all 
the local clinics has been hard; demands to produce protestors for ALL the 
doctors distributing abortifacient vaccines would be next to impossible. 
Furthermore, the decision to obtain the vaccine would be protected by doctor-
patient confidentiality and concealed in the privacy of a doctor's examining room. 
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With the destruction of life occurring so early after conception, the sense of 
personal responsibility for the destruction of unborn life is further diminished. In 
a sense, if there is no body, then there exists no crime. Since the vaccine destroys 
life at the early embryonic stage (the embryo is smaller than the dot on an "i"), a 
mother will never know that she was pregnant nor realize that her "birth control" 
killed her child. Society or the Church would have a difficult time speaking out 
against this technology if no visible corpse exists. Personal and public 
accountability will be greatly reduced as the life is destroyed so early in 
development. 
Self deception will strengthen as this technology proliferates. A birth control 
technology that removes the consequences of sexual intercourse may encourage 
further sexual immortality while at the same time ignore the monthly cost of an 
abortion within the womb. If the Church does not speak out against this 
technology before it arises commercially, it may have less influence as a moral 
guide afterwards. 
Furthermore, the Church may be faced with a future challenge to clearly 
confirm the sanctity of life even at the embryonic stage. There will arsie "pro-
vaccine advocates", who will justify the vaccine by declaring that the embryo is 
"not quite human" and therefore expendable. This mentality already exists as 
demonstrated by both the American Fertility Society and the NIH ad hoc 
committee endorsing human embryo research.8,IS The Church must then 
proceed with clear teachings on the sanctity of life at all stages of development. 
To do less, will condemn many unborn lives to a quiet death. 
E. Counterstrategies 
Perhaps one counterstrategy would combine public education in pro-life issues 
coupled with enhanced cooperation amongst pro-life forces and Christian 
churches. The first part will require advanced education on the possible side 
effects of vaccine technology as well as clearly stating the consequence of this 
technology; that is, it induces an abortion after each conception. Furthermore, 
pro-life forees and the Christian Church must continue to educate on issues such 
as reproduction and responsibility, the psychology oflove and sex, declaration of 
"life" at conception, adoption versus abortion, "safe sex", bioethics, abstinence, 
the value of life, etc. 
Beyond this, pro-life forces must increase their cooperation amongst the 
various pro-life organizations - religious or otherwise. This may require 
expanding communication and information exchange. One pro-life organizer 
told me some groups are fiercely competitive over information and on securing 
credit for information and events. In essence, they guard their work in a manner 
not unlike some secular corporations. Granted, fund raising for survival is 
necessary, but cooperation amongst pro-life forces will inevitably strengthen 
pro-life forces individually and corporately. 
This cooperation may require expanded communication on current issues, 
Biblical analysis, pro-life meetings and political events, protests, etc. via fax 
broadcasting technology, computer networks, and periodic teleconferencing. 
Finally, one argument against pro-life forces and the Church has been that they 
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do not care about the number of children a woman is FORCED to bear. 
Pro-life counterpoints have focused of God's timing of when and how many 
children to bear and natural family planning techniques. 
If pro-life really wants to regain the high ground in reproduction issues, it 
must examine technology as part of the answer. With the explosion of 
biotechnology, biosensors, microelectronics, medical diagnostics, etc., 
technology now exists (or may require some development) that would not 
induce an abortion and yet allow a safe, effective method of family planning. 
Several companies and many patents exist that would allow a rapid and 
accurate monitoring of a woman's fertility cycle; some even giving a day or 
two notice prior to ovulation. Yet how to get this technology into the hands 
of John Q. Public .. Jane Q .Public? 
Amidst the sea of pro-life members exist patent attorneys, entrepreneurs, 
investors, marketing specialists, doctors,scientists, engineers, manufacturing 
specialists, business administrators, etc. Put this mixture together and 
companies can be formed to develop, produce, and market this technology. 
Thus, from pro-life forces springs forth the pro-life technology which would 
easily surpass RU-486, Norplant, and abortifacient vaccines (as well as 
many other types of contraceptives!). 
Finally, the circle will be complete. From pro-life philosophy and 
theology, to education and communication, to finally the technology which 
achieves a respect for life (including the unborn) and a respect for 
reproductive responsibility. 
Conclusion 
In conclusion, abortifacient vaccine technology will present a new series 
of challenges to the Church, bioethicists, and pro-life organizations. The 
health hazards to the vacinne, and the possibility of using this technology for 
social engineering, will require effective education to the Church as a whole 
for many years to come. Quiet acceptance of this technology will only insure 
an increase in abortions, enhanced social apathy towards abortion, a 
continued cheapening of life, and the possibility of "immunologically 
sterile" vaccine recipients in the future. As the future of medicine progresses, 
the Church must clarify the repudiation of abortifacient vaccines as part its 
pro-life agenda. 
Furthermore, abortifacient vaccines present pro-life forces with a threat 
that goes beyond the clinic. It will present pro-life forces with a challenge to 
seek new strategies of education, communication, intergroup cooperation, 
and technological innovation. If they refuse this challenge, then pro-life 
forces must prepare to face atrophy of political, social, and counseling 
influence in American society. Sadly, if pro-life forces choose not to accept 
the challenge, they could wind up in the same historical wastebasket as the 
Women's Christian Temperance Union. The Whig Party, or the 
International Workers of the World (AKA Wobblies) Union . 
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